Subgroup analyses of data pooled from REACH and REACH‐2 have further confirmed the treatment benefit of ramucirumab in patients with advanced HCC who switched from sorafenib with elevated AFP,63 including specifically in patients in Japan,64 and regardless of aetiology of liver disease.65 Here, AFP is linked to hepatocellular carcinoma.